Abstract:Background Major depression comprises two discrete subtypes, major (MDMD) and simple (SDMD) dysmood disorder. MDMD, but not SDMD, patients were identified to have highly sensitized cytokine/growth factor networks using stimulated whole blood cultures. However, no information regarding serum cytokines/chemokines/growth factors in SDMD is available. Objectives This case-control study compares 48 serum cytokines/chemokines/growth factors in academic students with SDMD (n=64) and first episode (FE)-SDMD (n=47) to those of control students (n=44) using a multiplex assay. Findings Both FE-SDMD and SDMD exhibit a notable inhibition of immune profiles, such as the compensatory immunoregulatory response system (CIRS) and alternative M2 macrophage and T helper-2 (Th-2) profiles. We observed a substantial reduction in the serum concentrations of five proteins: interleukin (IL)-4, IL-10, soluble IL-2 receptor (sIL-2R), IL-12p40, and macrophage colony-stimulating factor. A significant proportion of the variability observed in suicidal behaviors (26.7%) can be accounted for by serum IL-4, IL-10, and sIL-2R (all decreased), and CCL11 (eotaxin) and granulocyte CSF (both increased). The same biomarkers (except for IL-10), accounted for 25.5% of the variance in SDMS severity. A significant correlation exists between decreased levels of IL-4 and elevated ratings of the brooding type of rumination. Conclusions The immune profile of SDMD and FE-SDMD exhibits a significant deviation from that observed in MDMD, providing additional evidence that SDMD and MDMD represent distinct phenotypes. SDMD is characterized by the suppression of the CIRS profile, which signifies a disruption of immune homeostasis and tolerance, rather than the presence of an inflammatory response. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The study was supported by the 90th Anniversary of Chulalongkorn University Scholarship under the Ratchadaphisek Somphot Fund (Batch#47), and the Ratchadaphisek Somphot Fund (Faculty of Medicine), MDCU (GA65/17), Chulalongkorn University, Thailand, to AV; and the Thailand Science Research, and Innovation Fund at Chulalongkorn University (HEA663000016), and a Sompoch Endowment Fund (Faculty of Medicine) MDCU (RA66/016) to MM. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The research project (IRB no.351/63) was approved by the Institutional Review Board of Chulalongkorn University's institutional ethics board, Bangkok, Thailand, which follows the International Guideline for Human Research protection as required by the Declaration of Helsinki, The Belmont Report, CIOMS Guideline and International Conference on Harmonization in Good Clinical Practice (ICH-GCP). All participants signed the appropriate institutional informed consent forms before data collection. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes MM will reply to reasonable requests for the dataset used in the current study after it has been fully utilized by all authors.

Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study

Linking peripheral IL-6, IL-1 and hypocretin-1 with cognitive impairment from major depression

Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder

Gut microbiota and inflammatory factor characteristics in major depressive disorder patients with anorexia

Relaitonship of mean platelet volume to MDD: a retrospecitve study

Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study

Major depressive disorder, neuroticism, suicidal behaviors, and depression severity are associated with cytokine networks and their intricate interactions with metabolic syndrome

Serum Interleukin Levels and Insulin Resistance in Major Depressive Disorder

Association between inflammatory cytokines and symptoms of major depressive disorder in adults

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Fluoxetine Treatment for Major Depression Decreases the Plasma Levels of Cytokines

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

Detection of Proinflammatory Cytokines in Serum Samples from Patients with Primary Major Depressive Disorder

Alterations of serum macro-minerals and trace elements are associated with major depressive disorder: a case-control study

The Plasma IL-18, MIP-1α, MCP-1, SDF-1 and Rantes in Patients with Majior Depression

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder

Mitogen-stimulated cell proliferation and cytokine production in major depressive disorder patients

Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design

Major Depression is Not an Inflammatory Disorder: Depletion of the Compensatory Immunoregulatory System is a Hallmark of a Mild Depression Phenotype

Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder

Study of decreased serum levels of C1q/TNF-related protein 4 (CTRP4) in major depressive disorder